Abdullah BÜYÜKÇELİK, Yasemin CİHAN BENDERLİ, Abdülsamet ERDEN, Tuncay ASLAN, Hediye UĞUR, Zeki AKÇA, Hasan MUTLU

Kanser hastalarında ortalama platelet volümü platelet sayısı, risk faktörleri ile tromboembolik olaylar arasındaki ilişki

Objective: For platelet volume, mean platelet volume is an indicator. We aimed to investigate the relationship among mean platelet volume, platelet count with thromboembolic event and detected risk factors for thromboemboli in patients who were newly diagnosed during one year follow-up. Material and Method: Consecutive 168 patients suffering from cancer have been followed-up for one year. Mean platelet volume an d platelet count, age, sex, cancer type, stage, comorbidity, smoking, chemotherapy intake and thromboembolic events were analysed. Results: While in the post treatment mean platelet volume a significant decrease was seen, post treatment platelet were counted as similar values according to first values at the time of diagnosis in patients of thromboembolic events (+). Chemotherapy intake and smoking were the risk factors for thromboemboli; smoking was the only independent one among these factors. Conclusion: During chemotherapy period, prophylaxis for thromboembolic event should be offered to the patients who were newly diagnosed with cancer for one year especially to whom with smoking.

The relationship among mean platelet volume, platelet count, risk factors and thromboembolic event in patients with cancer

PDF

___

1. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166(4):458-64.
2. Goldenberg N, Kahn SR, Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 2003;21(22):4194-9.
3. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004;103(6):2096-104.
4. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357(24):2482-94.
5. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999;340(2):115-26.
6. Alper AT, Akyol A, Hasdemir H, Yildirim A, Nurkalem Z, Güvenç TS, et al. Effect of cardiac resynchronization therapy on mean platelet volume. Acta Cardiol 2008;63(6):735-9.
7. Yavuz B, Ertugrul DT, Yalcin AA, Kucukazman M, Ata N, Dal K. Increased mean platelet volume in rheumatic mitral stenosis: a possible factor for thromboembolic events. J Cardiol 2009;53(2):204-7.
8. Gulcan M, Varol E, Etli M, Aksoy F, Kayan M. Mean platelet volume is increased in patients with deep vein thrombosis. Clin Appl Thromb Hemost 2012;18(4):427-30.
9. Varol E, Uysal BA, Ozaydin M. Platelet indices in patients with pulmonary arterial hypertension. Clin Appl Thromb Hemost 2011;17(6): E171-4.
10. Kosus N, Kosus A, Yildirim M, Duran M, Turhan NO. Mean platelet volume as a marker of thrombosis in patients with missed abortion. Acta Haematol 2011;125 (4): 208-9.
11. Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouschek W. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke 2004;35(7):1688-91.
12. Smith NM, Pathansali R, Bath PM. Platelets and stroke. Vasc Med 1999;4(3):16572.
13. Mutlu H, Berk V, Karaca H, Erden A, Aslan T, Akca Z. Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer. Clin Appl Thromb Hemost 2012;18(5):546-8.
14. Maraveyas A, Johnson M. Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Br J Cancer 2009;100(12):1837-41.
15. Lee AYY, Khorana AA, Vascular Events. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer Principles & Practice Oncology. 8th ed. 2008; 2635.
16. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285-91.
17. Svendsen E, Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 1989;42(8):805-9.
18. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002;87(6):1076- 7.
19. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343(25):1846-50.
20. Lee AYY, Khorana AA, Vascular Events. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer Principles & Practice Oncology. 8th ed. 2008; 2635-6.
21. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350(25):2558-63.
22. Gregg JP, Yamane AJ, Grody WW. Prevalence of the factor V- Leiden mutation in four distinct American ethnic populations. Am J Med Genet 1997;73(3):334-6.
23. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110(10):2339-46.
24. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA 1997;277(16):1305-7.
25. Pihusch R, Danzl G, Scholz M, Harich D, Pihusch M, Lohse P, et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 2002;94(12):3120-6.
26. Simanek R, Vormittag R, Ay C, Alguel G, Dunkler D, Schwarzinger I, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost 2010;8(1):114-20